EGFR (K716Q/L718Q)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.K716Q;p.L718Q
Components
p.K716Qp.L718Q
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Dacomitinib | 100.0% | 0.0% | 97.99 |
| 2 | Neratinib | 98.9% | 1.1% | 93.18 |
| 3 | Canertinib | 96.7% | 3.3% | 96.49 |
| 4 | Mobocertinib | 91.5% | 8.5% | 97.22 |
| 5 | Erlotinib | 89.1% | 10.9% | 99.75 |
| 6 | Lapatinib | 65.5% | 34.5% | 99.25 |
| 7 | Lazertinib | 59.2% | 40.8% | 97.47 |
| 8 | Osimertinib | 58.7% | 41.3% | 97.24 |
| 9 | Vandetanib | 55.8% | 44.2% | 95.74 |
| 10 | Imatinib | 48.4% | 51.6% | 99.00 |
| 11 | Defactinib | 43.8% | 56.2% | 92.68 |
| 12 | Fostamatinib | 41.8% | 58.2% | 96.74 |
| 13 | Ibrutinib | 33.4% | 66.6% | 94.74 |
| 14 | Trametinib | 32.4% | 67.6% | 99.50 |
| 15 | Baricitinib | 24.4% | 75.6% | 97.99 |
| 16 | Ribociclib | 24.2% | 75.8% | 99.25 |
| 17 | Zanubrutinib | 21.7% | 78.3% | 98.24 |
| 18 | Pralsetinib | 17.3% | 82.7% | 93.43 |
| 19 | Cabozantinib | 15.9% | 84.1% | 92.73 |
| 20 | Pazopanib | 15.4% | 84.6% | 97.49 |
| 21 | Dabrafenib | 14.0% | 86.0% | 94.74 |
| 22 | Temsirolimus | 13.0% | 87.0% | 100.00 |
| 23 | Umbralisib | 12.7% | 87.3% | 98.74 |
| 24 | Tofacitinib | 11.8% | 88.2% | 99.25 |
| 25 | Lenvatinib | 10.7% | 89.3% | 97.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Dacomitinib | 100.0% | 99.8% | +0.2% |
| Neratinib | 98.9% | 100.0% | -1.1% |
| Canertinib | 96.7% | 98.4% | -1.8% |
| Mobocertinib | 91.5% | 100.0% | -8.5% |
| Erlotinib | 89.1% | 99.4% | -10.3% |
| Lapatinib | 65.5% | 99.2% | -33.7% |
| Lazertinib | 59.2% | 100.0% | -40.8% |
| Osimertinib | 58.7% | 99.1% | -40.4% |
| Vandetanib | 55.8% | 99.3% | -43.5% |
| Imatinib | 48.4% | — | — |
| Defactinib | 43.8% | 94.6% | -50.8% |
| Fostamatinib | 41.8% | 97.8% | -56.0% |
| Ibrutinib | 33.4% | 99.3% | -66.0% |
| Trametinib | 32.4% | — | — |
| Baricitinib | 24.4% | — | — |
| Ribociclib | 24.2% | — | — |
| Zanubrutinib | 21.7% | 88.2% | -66.5% |
| Pralsetinib | 17.3% | 99.1% | -81.9% |
| Cabozantinib | 15.9% | — | — |
| Pazopanib | 15.4% | — | — |
| Dabrafenib | 14.0% | — | — |
| Temsirolimus | 13.0% | — | — |
| Umbralisib | 12.7% | — | — |
| Tofacitinib | 11.8% | — | — |
| Lenvatinib | 10.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 50.3ms